HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

XUANZHUBIO-B

8.880

-0.685-7.16%

Volume:1.37M

Turnover:12.42M

Market Cap:4.60B

PE:-14.35

High:9.555

Open:9.500

Low:8.765

Close:9.565

52wk High:96.900

52wk Low:8.765

Shares:518.00M

HK Float Shares:517.95M

Volume Ratio:0.30

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.619

ROE:-19.61%

ROA:-9.68%

PB:3.04

PE(LYR):-14.35

PS:38.12

Loading ...

Overview Company News Filings

Xuanzhu Biopharm initiates full electronic delivery of shareholder communications; urges investors to submit email contacts

Bulletin Express

玄珠生物-B(02575)2025年营收同比增长72%至0.52亿元多款肿瘤创新药完成商业化布局

Bulletin Express

Xuanzhu Biopharmaceutical publishes inaugural 2025 ESG report; R&D spend reaches RMB 183.84 million and Scope 1-2 emissions total 1,237 tCO₂e

Bulletin Express

Hong Kong Market Midday Update: Hang Seng Index Drops 1.12% in Morning Session, Coal Stocks Buck the Trend

Xuanzhu Bio-B Shares Surge Over 8% on NG-350A Phase 1b FORTRESS Study Preliminary Results Presentation at 2026 AACR

SIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR

CATL Shareholder Sets A-Share Transfer Price at 410.34 Yuan; Nitrogen Fertilizer Prices May Climb Further

Xuanzhu Biopharm: NG-350A Delivers 50% Composite Response in Early Phase 1b Rectal Cancer Trial at AACR 2026

Bulletin Express

Xuanzhu says Phase 1b NG-350A plus chemoradiotherapy hits 50% composite response rate

XUANZHUBIO-B to Present Phase III Data for Diraok in First-Line ALK-Positive Advanced NSCLC at 2026 AACR

Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%

Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares

Bulletin Express

XUANZHUBIO-B Receives Green Light from Hong Kong Stock Exchange for H-Share Full Circulation Plan

Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares

BUZZ-Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial

BRIEF-Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium

Stock Track | XUANZHUBIO-B Soars 6.13% at Market Open on Phase III Trial Approval for H. pylori Treatment

XuanZhu Bio-B Receives Approval for Phase III Trial of New Anaprazole Sodium Indication

XUANZHUBIO-B Wins CDE Approval to Launch 556-Patient Phase III Trial of Anaprazole Sodium for H. pylori Eradication

Bulletin Express

Xuanzhu Biopharma wins China CDE nod for Phase III Anaprazole H. pylori trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/02575/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":8.88,"timestamp":1789027724004,"preClose":9.565,"halted":0,"volume":1365500,"delay":0,"changeRate":-0.07161526398327221,"floatShares":517947790,"shares":518000000,"eps":-0.6189629943303457,"marketStatus":"Not Yet Opened","change":-0.685,"latestTime":"09-10 16:08:44","open":9.5,"high":9.555,"low":8.765,"amount":12420785,"amplitude":0.082593,"askPrice":8.88,"askSize":6500,"bidPrice":8.865,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.49184784882489946,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":9.565,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.3009555023089365,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":517947790,"roa":"-9.68%","roe":"-19.61%","lyrEps":-0.618968,"volumeRatio":0.3009555023089365,"shares":518000000,"dividePrice":0,"high":9.555,"amplitude":0.082593,"preClose":9.565,"low":8.765,"week52Low":8.765,"pbRate":"3.04","psRate":"38.12","week52High":96.9,"institutionHeld":0,"latestPrice":8.88,"committee":-0.733333,"eps":-0.6189678481806776,"divideRate":0,"volume":1365500,"delay":0,"ttmEps":-0.4918517058500627,"open":9.5,"prevYearClose":70.5,"prevWeekClose":10.43,"prevMonthClose":10.08,"prevQuarterClose":13.33,"fiveDayClose":11.12,"twentyDayClose":12.39,"sixtyDayClose":16.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"date":"2026-03-30","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2026-09-09","current":-18.051637,"percent":0.963636,"low":-70.039607,"twenty":-55.062726,"median":-42.005079,"eighty":-24.075629,"high":-18.714723,"avg":-41.045751,"sd":14.501145,"marketCap":4954170611},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170},{"date":"2025-11-21","current":-53.748657,"twenty":-55.319259,"median":-54.136108,"eighty":-50.782713,"marketCap":32734300328},{"date":"2025-11-28","current":-53.384655,"twenty":-55.070724,"median":-54.15954,"eighty":-50.923112,"marketCap":32630710770},{"date":"2025-12-05","current":-54.773392,"twenty":-55.070724,"median":-54.21583,"eighty":-51.627953,"marketCap":33537119402},{"date":"2025-12-12","current":-70.039607,"twenty":-55.665823,"median":-54.261136,"eighty":-53.311356,"marketCap":42963769180},{"date":"2025-12-19","current":-60.019152,"twenty":-56.570931,"median":-54.488669,"eighty":-53.433833,"marketCap":36903780037},{"date":"2025-12-24","current":-59.160975,"twenty":-59.157371,"median":-54.549256,"eighty":-53.581365,"marketCap":36489421805},{"date":"2026-01-02","current":-54.537602,"twenty":-59.158272,"median":-54.690337,"eighty":-53.655303,"marketCap":33770195908},{"date":"2026-01-09","current":-52.983682,"twenty":-59.049917,"median":-54.49123,"eighty":-52.274882,"marketCap":32889684665},{"date":"2026-01-16","current":-58.758617,"twenty":-58.846722,"median":-54.572443,"eighty":-53.169291,"marketCap":36593011363},{"date":"2026-01-23","current":-52.071916,"twenty":-58.705513,"median":-54.4959,"eighty":-52.506318,"marketCap":32397634264},{"date":"2026-01-30","current":-53.326607,"twenty":-57.909955,"median":-54.48995,"eighty":-52.506318,"marketCap":33329940286},{"date":"2026-02-06","current":-57.283358,"twenty":-57.848985,"median":-54.4959,"eighty":-52.506318,"marketCap":35893781847},{"date":"2026-02-13","current":-51.942748,"twenty":-58.578655,"median":-54.516751,"eighty":-52.506318,"marketCap":32734300328},{"date":"2026-02-20","current":-51.153455,"twenty":-58.517685,"median":-54.493565,"eighty":-52.321662,"marketCap":32190455148},{"date":"2026-02-27","current":-53.732962,"twenty":-57.403185,"median":-54.403912,"eighty":-52.138331,"marketCap":34184554140},{"date":"2026-03-06","current":-41.037619,"twenty":-57.295346,"median":-54.261136,"eighty":-51.687579,"marketCap":25897389500},{"date":"2026-03-13","current":-40.849477,"twenty":-57.283358,"median":-54.21583,"eighty":-50.904735,"marketCap":25897389500},{"date":"2026-03-20","current":-35.26408,"twenty":-56.603099,"median":-54.112473,"eighty":-49.228933,"marketCap":22271754970},{"date":"2026-03-27","current":-28.858752,"twenty":-56.47148,"median":-53.935449,"eighty":-43.741043,"marketCap":18179967429},{"date":"2026-04-02","current":-57.594339,"twenty":-56.497804,"median":-53.833069,"eighty":-43.169536,"marketCap":16087458357},{"date":"2026-04-10","current":-59.545661,"twenty":-57.25627,"median":-53.970491,"eighty":-43.400861,"marketCap":16760790484},{"date":"2026-04-17","current":-61.727863,"twenty":-57.517877,"median":-54.136108,"eighty":-43.645588,"marketCap":17382327832},{"date":"2026-04-24","current":-45.649544,"twenty":-57.360049,"median":-54.047185,"eighty":-44.053945,"marketCap":12855464147},{"date":"2026-04-30","current":-39.643505,"twenty":-57.292948,"median":-53.884259,"eighty":-43.829171,"marketCap":11166954352},{"date":"2026-05-08","current":-39.029961,"twenty":-57.269814,"median":-53.732962,"eighty":-42.509315,"marketCap":11032287927},{"date":"2026-05-15","current":-34.724128,"twenty":-57.211578,"median":-53.651177,"eighty":-40.906347,"marketCap":9841008010},{"date":"2026-05-22","current":-32.788719,"twenty":-57.162996,"median":-53.511235,"eighty":-40.250137,"marketCap":9271265441},{"date":"2026-05-29","current":-29.882198,"twenty":-57.033621,"median":-53.326607,"eighty":-39.029961,"marketCap":8478805322},{"date":"2026-06-05","current":-31.916861,"twenty":-56.603099,"median":-53.185623,"eighty":-36.605471,"marketCap":9069265802},{"date":"2026-06-12","current":-29.603728,"twenty":-56.47148,"median":-52.629422,"eighty":-35.26408,"marketCap":8406292631},{"date":"2026-06-18","current":-30.479088,"twenty":-56.448102,"median":-52.321662,"eighty":-34.687576,"marketCap":8675625482},{"date":"2026-06-26","current":-23.369212,"twenty":-56.068362,"median":-52.035899,"eighty":-32.252252,"marketCap":6619372756},{"date":"2026-07-03","current":-26.037742,"twenty":-55.925853,"median":-51.815163,"eighty":-31.259875,"marketCap":7380756007},{"date":"2026-07-10","current":-23.563382,"twenty":-55.788956,"median":-51.211683,"eighty":-30.461424,"marketCap":6671167535},{"date":"2026-07-17","current":-22.969392,"twenty":-55.712025,"median":-50.877852,"eighty":-29.911789,"marketCap":6526142154},{"date":"2026-07-24","current":-21.396832,"twenty":-55.583366,"median":-50.208288,"eighty":-29.704477,"marketCap":6080707054},{"date":"2026-07-31","current":-19.991935,"twenty":-55.489987,"median":-48.334812,"eighty":-29.33959,"marketCap":5692246212},{"date":"2026-08-07","current":-22.658402,"twenty":-55.433258,"median":-45.681548,"eighty":-28.96324,"marketCap":6463988419},{"date":"2026-08-14","current":-22.412159,"twenty":-55.37071,"median":-44.835824,"eighty":-28.336789,"marketCap":6401834684},{"date":"2026-08-21","current":-20.01067,"twenty":-55.365612,"median":-44.352491,"eighty":-26.122142,"marketCap":5728502557},{"date":"2026-08-28","current":-22.359148,"twenty":-55.267771,"median":-43.581952,"eighty":-25.329792,"marketCap":5474708140},{"date":"2026-09-04","current":-22.054147,"twenty":-55.10047,"median":-42.591003,"eighty":-24.406781,"marketCap":5402195449},{"date":"2026-09-09","current":-20.192794,"twenty":-55.062726,"median":-42.005079,"eighty":-24.075629,"marketCap":4954170611}],"updateTime":1789061557456},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1157313573","title":"Xuanzhu Biopharm initiates full electronic delivery of shareholder communications; urges investors to submit email contacts","url":"https://stock-news.laohu8.com/highlight/detail?id=1157313573","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157313573?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:03","pubTimestamp":1777291390,"startTime":"0","endTime":"0","summary":"On 28 April 2026, Xuanzhu Biopharmaceutical Co., Ltd. (“Xuanzhu Biopharm”) issued a reminder to its registered shareholders confirming the transition to electronic dissemination of all corporate...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161574939","title":"玄珠生物-B(02575)2025年营收同比增长72%至0.52亿元 多款肿瘤创新药完成商业化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1161574939","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161574939?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:47","pubTimestamp":1777290440,"startTime":"0","endTime":"0","summary":"玄珠生物-B（02575）公布截至2025年12月31日止年度业绩，年内实现营收约0.52亿元（较上年同期的0.30亿元增长72.0%），主要来自产品销售规模扩大与商业化推进。公司期内经营效率提升，全年净亏损较上年同期大幅收窄55.9%至约2.46亿元，显示收入增长与费用优化带来的运营杠杆效应。...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"玄珠生物-B(02575)2025年营收同比增长72%至0.52亿元 多款肿瘤创新药完成商业化布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144640823","title":"Xuanzhu Biopharmaceutical publishes inaugural 2025 ESG report; R&D spend reaches RMB 183.84 million and Scope 1-2 emissions total 1,237 tCO₂e","url":"https://stock-news.laohu8.com/highlight/detail?id=1144640823","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144640823?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:43","pubTimestamp":1777290200,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. released its first Environmental, Social and Governance (ESG) report covering the 2025 fiscal year. The document outlines governance enhancements, climate-related...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168267258","title":"Hong Kong Market Midday Update: Hang Seng Index Drops 1.12% in Morning Session, Coal Stocks Buck the Trend","url":"https://stock-news.laohu8.com/highlight/detail?id=1168267258","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168267258?lang=en_us&edition=fundamental","pubTime":"2026-04-23 12:12","pubTimestamp":1776917553,"startTime":"0","endTime":"0","summary":"The Hang Seng Index declined by 1.12%, shedding 292 points to reach 25,870. The Hang Seng Tech Index fell by 2.31%. Morning session turnover reached HK$142.6 billion. LOPAL TECH (02465) surged over...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XPEV","02635","603906","HSTECH","600988","YZCAY","02833","01797","HHImain","600029","MCHmain","06181","09868","513600","00568","BK4585","HSI","03330","01055","GWLLY","BK1616","002490","02589","BK1110","06693","BK1233","601633","02883","BK4588","02575","600188","HTImain","02465","601808","HSImain","01171","03668","600115","00670","02333","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174006676","title":"Xuanzhu Bio-B Shares Surge Over 8% on NG-350A Phase 1b FORTRESS Study Preliminary Results Presentation at 2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=1174006676","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174006676?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:10","pubTimestamp":1776913837,"startTime":"0","endTime":"0","summary":"Xuanzhu Bio-B (02575) saw its shares rise more than 8% during the trading session. As of the time of writing, the stock had climbed 8.65% to HK$28.4, with a turnover of HK$119 million. On April 20,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VXUS","02575","BK1191","BK4017","NG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141536607","title":"SIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=1141536607","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141536607?lang=en_us&edition=fundamental","pubTime":"2026-04-21 11:40","pubTimestamp":1776742822,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) rose nearly 3%, with the stock up 2.29% to HK$1.34 at the time of writing. Turnover reached HK$18.04 million. The increase follows an announcement on April 20 that the group's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1593","BK1600","BK1515","VXUS","00460","BK4588","BK4585","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113433094","title":"CATL Shareholder Sets A-Share Transfer Price at 410.34 Yuan; Nitrogen Fertilizer Prices May Climb Further","url":"https://stock-news.laohu8.com/highlight/detail?id=1113433094","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113433094?lang=en_us&edition=fundamental","pubTime":"2026-04-21 07:40","pubTimestamp":1776728442,"startTime":"0","endTime":"0","summary":"Global nitrogen fertilizer exporter Fertiglobe indicated that nitrogen fertilizer prices have surged to nearly double pre-Iran conflict levels and could rise further as key supplies remain blocked in...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBLUY","LU0405327148.USD","LU0188438112.USD","LU0048575426.USD","LU2360107325.USD","LU0269904917.USD","SG9999004220.SGD","BK4526","LU2153591404.USD","LU1969619763.USD","LU2097828631.EUR","META","00941","BK1116","BK1554","LU0011963245.USD","LU0650527681.SGD","LU2357125470.USD","PLUG","LU2298322129.HKD","LU1102505929.USD","LU0505663152.USD","SG9999001689.USD","02691","BK1515","LU0029875118.USD","LU0231483743.USD","LU1769817179.HKD","LU0456827905.SGD","LU2041044095.USD","IE00B5MMRT66.SGD","LU2275660780.HKD","06608","LU0048388663.USD","LU0828238088.HKD","SG9999002828.SGD","LU2148510915.USD","SNFRY","LU0651946864.USD","EVS.SI","LU1951186391.HKD","SG9999000327.SGD","HK0000181138.USD","LU0143863784.USD","LU0531970944.HKD","600941","LU0043850808.USD","LU2506952337.HKD","LU1242518857.USD","LU0165289439.USD","LU0501845795.SGD","LU0072462343.USD","LU0979878070.USD","LU1048588211.SGD","LU0531971595.HKD","SG9999001846.SGD","BK0224","HK0000181112.HKD","LU0312595415.SGD","LU0516423091.SGD","LU2125910500.SGD","SGXZ81163826.USD","IE00B29SXG58.USD","LU0106259558.USD","LU0214875030.USD","LU0449509016.USD","BK4519","LU0359202008.SGD","LU0821914370.USD","LU0828237940.HKD","LU2394011477.USD","LU1868837565.USD","LU1813983027.USD","IE0008369823.USD","LU0047713382.USD","03200","LU0516422366.SGD","LU0049853897.USD","LU0244354667.USD","LU0594300419.USD","LU0880133367.SGD","LU1064131003.USD","SG9999000459.SGD","LU1831875114.USD","LU0192582467.USD","IE0032431581.USD","LU0254981946.USD","LU2476274720.SGD","LU3063872942.SGD","SG9999002463.SGD","02476","LU0048580855.USD","LU0039217434.USD","LU0261950470.USD","IE00B8HQ1Z84.USD","LU1064130708.USD","LU2249611893.SGD","300750","LU1997245094.SGD","01093","LU2506952410.USD","LU0327786744.USD","LU1226287792.SGD","LU0651947912.USD","00297","LU1188198961.HKD","LU1861219969.SGD","LU0181495838.USD","LU0302445910.USD","LU1861214812.USD","LU2097828474.EUR","LU0314109678.HKD","LU0823437842.USD","LU0072913022.USD","LU1242518931.SGD","LU1794554557.SGD","LU2580892862.HKD","LU2477742899.HKD","LU2092937221.SGD","LU2778985437.USD","SGXZ49509284.SGD","00719","LU0823426480.USD","LU1939255532.USD","LU0259732245.USD","LU0140636845.USD","LU0067412154.USD","LU0605514214.HKD","BK1610","LU0823414478.USD","LU1146622755.USD","IE0003795394.USD","00451","LU0149534421.HKD","LU0164872284.USD","LU1997244956.HKD","TSLA","301200","LU0124384867.USD","LU1880383440.USD","LU1934453819.USD","LU2294711713.HKD","LU0210526637.USD","IE00B8L5B284.USD","LU1152091754.HKD","LU1655091616.SGD","BK1129","BK1147","02575","LU2298321311.HKD","LU1580142542.USD","LU1720050803.USD","LU1515016050.SGD","LU0823426308.USD","LU1226287875.USD","LU0251143458.SGD","IE00BZ08YR35.GBP","LU2097828714.EUR","LU1008478684.HKD","LU1993786604.SGD","LU1721428347.USD","002466","03750","LU0228659784.USD","LU0235996351.USD","LU1051769294.HKD","LU2153592121.USD","LU2348773727.SGD","LU0326950275.SGD","INTC","SG9999003461.SGD","LU2125910849.SGD","LU2298064838.USD","BK1521","BK4588","LU1226288253.USD","601607","LU2348774022.SGD","LU0516423174.USD","LU1719994722.HKD","LU0405327494.USD","LU1102505762.USD","SG9999014674.SGD","LU2097828805.USD","LU2238339852.HKD","BK1594","IE00BD6J9T35.USD","SHPMY","LU1880383366.USD","LU2476274308.USD","LU1770034418.SGD","IE00BZ08YT58.USD","LU2424517915.HKD","LU1226288170.HKD","LU0320764755.SGD","LU0611395673.USD","LU1255011170.USD","LU1960683339.HKD","LU0107464264.USD","LU0502904849.HKD","02607","LU0469268626.HKD","LU0607220059.USD","IE00BZ08YS42.EUR","SG9999001903.USD","LU0516422952.EUR","LU1023057109.AUD","300476","LU1769817096.USD","000756","LU2045819591.USD","BK1154","LU1807302812.USD","01866","03393","LU0823414551.USD","LU0672654166.SGD","LU0543330483.HKD","COIN","LU2360108059.USD","BK4141","BK4585","LU0572944931.SGD","LU1868838027.USD","LU1978683503.SGD","LU2506951792.HKD","LU1152091168.USD","LU2399975544.HKD","LU2152927971.USD","LU0724618433.USD","LU1781817850.SGD","LU1039395188.USD","LU2289578879.USD","LU0359201612.USD","LU0359201885.HKD","LU0509642566.USD","LU1961090484.USD","LU2580892789.USD","LU1328277881.USD","IE00B031HY20.USD","LU0328353924.USD","LU2328871848.SGD","LU0594300179.USD","HK0000165453.HKD","LU0106252389.USD","LU0051755006.USD","LU0164865239.USD","LU1251922891.USD","LU0132412106.USD","03983","IE00B3M56506.USD","LU0128522157.USD","LU2506952253.HKD","IE0008368742.USD","LU2242644610.SGD","IE00BPRC5H50.USD","LU0828237510.HKD","LU2294711473.HKD","LU0315179316.USD","LU0326948709.USD","LU1820825898.SGD","LU0593848301.USD","04335","LU0348805143.USD","LU0449515922.USD","LU0455707207.USD","IE00BZ199S13.USD","LU0463099449.HKD","LU1979443071.USD","LU2495084118.USD","LU1303224171.USD","LU1997245177.USD","LU0106959298.USD","IE00B543WZ88.USD","LU2449936058.SGD","LU0516422440.USD","LU1808992512.USD","LU0054450605.USD","LU0871576103.HKD","LU0370786039.SGD","LU1226287529.USD","LU2097828557.USD","LU0143863198.USD","09696","BK1191","LU1051768304.USD","IE0003851619.USD","LU1048596156.SGD","LU2039709279.SGD","603093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156604450","title":"Xuanzhu Biopharm: NG-350A Delivers 50% Composite Response in Early Phase 1b Rectal Cancer Trial at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1156604450","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156604450?lang=en_us&edition=fundamental","pubTime":"2026-04-20 17:03","pubTimestamp":1776675811,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharm) reported preliminary data from the ongoing Phase 1b FORTRESS study evaluating NG-350A combined with chemoradiotherapy (CRT) in patients with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628574340","title":"Xuanzhu says Phase 1b NG-350A plus chemoradiotherapy hits 50% composite response rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2628574340","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628574340?lang=en_us&edition=fundamental","pubTime":"2026-04-20 16:51","pubTimestamp":1776675091,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical announced preliminary Phase 1b FORTRESS data for NG-350A were presented at 2026 AACR on April 20, 2026.Early results indicated NG-350A combined with chemoradiotherapy improved response outcomes in mismatch repair-proficient locally advanced rectal cancer versus expectations for chemoradiotherapy alone.Safety profile appeared supportive, with no serious adverse events or new safety signals attributed to NG-350A in initial patients completing active treatment.Program supports Xuanzhu strategy to advance NG-350A development in Greater China under an exclusive license from Akamis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL95R4QQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","02575","BK1191","BK1593","BK1515","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126932556","title":"XUANZHUBIO-B to Present Phase III Data for Diraok in First-Line ALK-Positive Advanced NSCLC at 2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=1126932556","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126932556?lang=en_us&edition=fundamental","pubTime":"2026-04-19 18:20","pubTimestamp":1776594034,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that the Group presented results from the Phase III DIAMOND-2 clinical study of Diraok as a first-line treatment for anaplastic lymphoma kinase (ALK) positive advanced...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ALK","02575","BK1191","BK4008","III","BK4585","BK4134","BK4500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628076134","title":"Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628076134","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628076134?lang=en_us&edition=fundamental","pubTime":"2026-04-19 18:07","pubTimestamp":1776593223,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical presented Phase III DIAMOND-2 trial results for ALK-positive advanced non-small cell lung cancer at 2026 AACR, held April 17-22, 2026.Dirozalkib outperformed crizotinib in first-line treatment, extending time without disease worsening in a 275-patient China study.Study also showed stronger tumor shrinkage durability, including improved control of brain lesions versus comparator.Safety profile supported continued use, with mostly mild-to-moderate gastrointestinal side effects.Dirozalkib received China NMPA clearance in August 2025 for ALK-positive locally advanced or metastatic NSCLC in patients not previously treated with an ALK inhibitor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nNDL4PxWxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","02575","BK1191","BK1593","BK1515","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124608444","title":"Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1124608444","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124608444?lang=en_us&edition=fundamental","pubTime":"2026-04-17 17:05","pubTimestamp":1776416700,"startTime":"0","endTime":"0","summary":"Hong Kong – Xuanzhu Biopharmaceutical Co., Ltd. announced that the Hong Kong Stock Exchange has approved the listing and dealing of 357.25 million H shares converted from unlisted shares under its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189853321","title":"XUANZHUBIO-B Receives Green Light from Hong Kong Stock Exchange for H-Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1189853321","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189853321?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:34","pubTimestamp":1776414856,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that on April 16, 2026, the Hong Kong Stock Exchange approved the listing and trading of 357 million H-shares. These shares will be converted from non-traded shares as...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628134279","title":"Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2628134279","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628134279?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:31","pubTimestamp":1776414695,"startTime":"0","endTime":"0","summary":"Hong Kong stock exchange cleared Xuanzhu Biopharmaceutical to list 357,245,794 H shares converted from unlisted shares under its H-share full circulation plan.Transaction would lift total listed H shares to 517,947,790 from 160,701,996 once conversion and trading procedures are completed.Xuanzhu flagged additional updates as it moves toward completion of conversion and listing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL24Xh0W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1191","00460","BK1593","02575","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627502471","title":"BUZZ-Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627502471","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627502471?lang=en_us&edition=fundamental","pubTime":"2026-04-15 10:21","pubTimestamp":1776219698,"startTime":"0","endTime":"0","summary":"BUZZ-Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial    ** Shares of Xuanzhu Biopharmaceutical 2575.HK jump as much as 25.8% to HK$41, their highest level since March 26** Stock marks its biggest one-day pct rise since October 22** Xuanzhu says China's National Medical Products Administration has approved the company to initiate a Phase III clinical trial of bismuth-containing quadruple therapy comprising Anaprazole Sodium Enteric-coated tablets for the eradication of Helicobacter pylori** The market size of drugs for treatment of Helicobacter pylori, which closely associated with gastric diseases including gastric ulcer, chronic progressive gastritis and gastric cancer, reached 5.5 billion yuan  in 2024, and is projected to reach 6.8 billion yuan in 2029 and to 12.6 billion yuan in 2035, says Xuanzhu ** The approval of the Phase III clinical trial application for the new indication of Anaprazole Sodium helps to enhance the company's influence in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nL1N40Y01E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1191","BK1593","BK1515","02575","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627576479","title":"BRIEF-Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium","url":"https://stock-news.laohu8.com/highlight/detail?id=2627576479","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627576479?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:48","pubTimestamp":1776217723,"startTime":"0","endTime":"0","summary":"BRIEF-Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium April 15  - Xuanzhu Biopharmaceutical 2575.HK:APPROVED TO INITIATE PHASE III TRIAL OF ANAPRAZOLE SODIUM FOR HELICOBACTER PYLORI ERADICATIONFurther company coverage: 2575.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40X16Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180494741","title":"Stock Track | XUANZHUBIO-B Soars 6.13% at Market Open on Phase III Trial Approval for H. pylori Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1180494741","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180494741?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:38","pubTimestamp":1776217086,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B's stock soared 6.13% at the market open on Wednesday, following the announcement of a significant regulatory milestone for its key drug candidate.The biopharmaceutical company received...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194755077","title":"XuanZhu Bio-B Receives Approval for Phase III Trial of New Anaprazole Sodium Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1194755077","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194755077?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:38","pubTimestamp":1776206301,"startTime":"0","endTime":"0","summary":"XuanZhu Bio-B (02575) announced that its self-developed innovative drug, Anaprazole Sodium Enteric-Coated Tablets (brand name: Anjiuwe®), has recently received approval from the Center for Drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161699163","title":"XUANZHUBIO-B Wins CDE Approval to Launch 556-Patient Phase III Trial of Anaprazole Sodium for H. pylori Eradication","url":"https://stock-news.laohu8.com/highlight/detail?id=1161699163","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161699163?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:20","pubTimestamp":1776205235,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (XUANZHUBIO-B) has secured authorisation from China’s Center for Drug Evaluation to begin a multi-centre Phase III study evaluating a bismuth-containing quadruple...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627542752","title":"Xuanzhu Biopharma wins China CDE nod for Phase III Anaprazole H. pylori trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627542752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627542752?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:07","pubTimestamp":1776204421,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical secured China CDE clearance to start Phase III trial of bismuth-containing quadruple therapy using Anaprazole Sodium for Helicobacter pylori eradication.Study targets enrollment of 556 adults, with primary endpoint H. pylori eradication rate confirmed by 13C-urea breath test on day 28.Anaprazole Sodium was approved in China in June 2023 for duodenal ulcer, with new Phase III program aimed at expanding its label into digestive diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 14, 2026, and is solely responsible for ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL9fwX0k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","02575","BK1191","BK1593","00460","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":85,"code":"91000000","status":"200"}]}}